Coherus Oncology, Inc. (CHRS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Coherus Oncology reported revenue of $42.2M, down 84.2% from $267.0M the year before. Net income was $168.0M (a 398.4% net margin), or $1.43 per diluted share. Gross margin was 67.2% and operating margin was -429.5%. Operating activities generated -$138.5M of cash. At fiscal year end, Coherus Oncology held $258.3M in total assets against $197.3M in total liabilities, including $88.9M of cash and equivalents.
Open the full interactive Coherus Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Coherus Oncology Key Stats
| Share Price | $1.07 |
|---|---|
| Market Cap | $165.7M |
| P/E Ratio | 0.7 |
| Revenue YoY Growth | -84.2% |
| 52-Week Range | $1.01 – $2.51 |
| Shares Outstanding | 154.8 million (basic, 2026 Q2) |
Coherus Oncology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $475.8M | $326.6M | $211.0M | $257.2M | $267.0M | $42.2M |
| Cost of Goods Sold | $37.7M | $57.6M | $70.1M | $159.0M | $117.6M | $13.8M |
| Gross Profit | $438.2M | $269.0M | $141.0M | $98.3M | $149.4M | $28.4M |
| Operating Income | $156.3M | -$263.9M | -$256.9M | -$203.2M | -$111.7M | -$181.1M |
| Pre-Tax Income | $135.7M | -$287.1M | -$291.8M | -$238.3M | $28.5M | -$183.1M |
| Income Tax | $3.5M | $0 | $0 | -$380,000 | — | $0 |
| Net Income | $132.2M | -$287.1M | -$291.8M | -$237.9M | $28.5M | $168.0M |
| Diluted EPS | $1.62 | -$3.81 | -$3.76 | -$2.53 | $0.25 | $1.43 |
Coherus Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $11.6M | $12.7M | $12.3M | $14.3M |
| Net Income | -$35.5M | -$37.6M | -$38.3M | -$20.6M |
| Diluted EPS | -$0.31 | -$0.32 | -$0.28 | -$0.13 |
Coherus Oncology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $541.2M | $417.2M | $63.5M | $102.9M | $126.0M | $88.9M |
| Current Assets | $767.5M | $602.3M | $381.2M | $475.6M | $341.6M | $206.7M |
| Total Assets | $841.6M | $679.3M | $480.8M | $629.6M | $448.5M | $258.3M |
| Current Liabilities | $145.7M | $165.3M | $138.7M | $331.8M | $283.0M | $140.4M |
| Total Long-Term Debt | $154.4M | $156.9M | — | — | — | — |
| Total Liabilities | $560.7M | $581.6M | $618.3M | $823.0M | $580.5M | $197.3M |
| Shareholders' Equity | $281.0M | $97.7M | -$137.4M | -$193.4M | -$132.0M | $61.0M |
Coherus Oncology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $154.1M | -$37.4M | -$241.1M | -$174.9M | -$20.4M | -$138.5M |
| Cash From Investing | -$14.4M | -$138.4M | -$166.8M | $144.6M | $230.3M | $375.1M |
| Cash From Financing | $223.9M | $51.9M | $54.3M | $69.6M | -$187.0M | -$273.7M |
| Free Cash Flow | $146.9M | -$38.7M | -$243.2M | -$175.2M | — | — |
Figures from Coherus Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Coherus Oncology financials page for every line item.
Coherus Oncology Company Profile
| Ticker | CHRS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Redwood City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer, smaller reporting company |
| SEC CIK | 0001512762 |
Frequently Asked Questions
What was Coherus Oncology's revenue in fiscal 2025?
Coherus Oncology (CHRS) reported revenue of $42.2M for fiscal 2025.
What is Coherus Oncology's annual revenue history?
Coherus Oncology's annual revenue by fiscal year: 2020: $475.8M; 2021: $326.6M; 2022: $211.0M; 2023: $257.2M; 2024: $267.0M; 2025: $42.2M.
What was Coherus Oncology's net income in fiscal 2025?
Coherus Oncology reported net income of $168.0M for fiscal 2025.
What was Coherus Oncology's earnings per share (EPS) in fiscal 2025?
Coherus Oncology's diluted EPS was $1.43 for fiscal 2025 (adjusted for any later stock splits).
What was Coherus Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Coherus Oncology reported revenue of $14.3M.
How many shares of Coherus Oncology are outstanding?
Coherus Oncology reported a weighted average of 154.8 million basic shares outstanding in 2026 Q2.
What is Coherus Oncology's market cap?
Based on its latest closing price, Coherus Oncology (CHRS) has a market capitalization of about $165.7M.
When does Coherus Oncology's fiscal year end?
Coherus Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Coherus Oncology headquartered?
Coherus Oncology lists its business address in Redwood City, California in its SEC filings.
Coherus Oncology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →